Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Perrotte

Showing results (11-20 of 245) with videos related to

Pageof 25
Sort By:
Urologic Oncology|December 25, 2003
Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatinLance C Pagliaro, Afsaneh Keyhani, Baoshun Liu, et al.
BJU International|May 12, 2006
Normal urinary and sexual function in men without evidence of prostate cancer from Montreal, CanadaDaniel J Lewinshtein, Paul Perrotte, Thierry Lebeau, et al.
European Urology|November 28, 2006
Sunitinib relieves renal cell carcinoma spinal cord compressionQuoc-Dien Trinh, Etienne Cardinal, Andrea Gallina, et al.
The Canadian Journal of Urology|January 13, 2006
Validation of prostate cancer index and SF-12 short formsThierry Lebeau, Paul Perrotte, Luc Valiquette, et al.
The Canadian Journal of Urology|September 6, 2006
Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experiencePierre I Karakiewicz, Serge Benayoun, Daniel J Lewinshtein, et al.
European Urology|December 7, 2007
Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombiPierre I Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al.
The Journal of Sexual Medicine|January 29, 2008
The effect of comorbidities and socioeconomic status on sexual and urinary function in men undergoing prostate cancer screeningNaeem Bhojani, Paul Perrotte, Claudio Jeldres, et al.
BJU International|May 31, 2008
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisoneFred Saad, Dean Ruether, Scott Ernst, et al.
Future Oncology (London, England)|March 13, 2010
Effect of the number of biopsy cores on prostate cancer detection and stagingGiovanni Lughezzani, Maxine Sun, Lars Budäus, et al.
Endocrine Oncology (Bristol, England)|July 12, 2023
Adrenocortical cancer recurrence following initial transcutaneous biopsy: a rare demonstration of needle tract seedingNada Younes, Isabelle Bourdeau, Harold Olney, et al.
Pageof 25

Showing results (11-20 of 245) with videos related to

Sort By:
Pageof 25
Urologic Oncology|December 25, 2003
Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatinLance C Pagliaro, Afsaneh Keyhani, Baoshun Liu, et al.
BJU International|May 12, 2006
Normal urinary and sexual function in men without evidence of prostate cancer from Montreal, CanadaDaniel J Lewinshtein, Paul Perrotte, Thierry Lebeau, et al.
European Urology|November 28, 2006
Sunitinib relieves renal cell carcinoma spinal cord compressionQuoc-Dien Trinh, Etienne Cardinal, Andrea Gallina, et al.
The Canadian Journal of Urology|January 13, 2006
Validation of prostate cancer index and SF-12 short formsThierry Lebeau, Paul Perrotte, Luc Valiquette, et al.
The Canadian Journal of Urology|September 6, 2006
Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experiencePierre I Karakiewicz, Serge Benayoun, Daniel J Lewinshtein, et al.
European Urology|December 7, 2007
Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombiPierre I Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al.
The Journal of Sexual Medicine|January 29, 2008
The effect of comorbidities and socioeconomic status on sexual and urinary function in men undergoing prostate cancer screeningNaeem Bhojani, Paul Perrotte, Claudio Jeldres, et al.
BJU International|May 31, 2008
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisoneFred Saad, Dean Ruether, Scott Ernst, et al.
Future Oncology (London, England)|March 13, 2010
Effect of the number of biopsy cores on prostate cancer detection and stagingGiovanni Lughezzani, Maxine Sun, Lars Budäus, et al.
Endocrine Oncology (Bristol, England)|July 12, 2023
Adrenocortical cancer recurrence following initial transcutaneous biopsy: a rare demonstration of needle tract seedingNada Younes, Isabelle Bourdeau, Harold Olney, et al.
Pageof 25